Similar articles

• A prospective randomized comparison of prophylactic ALG and OKT3 in cadaver kidney allograft recipients.

  Hanto DW, Jendrisak MD, McCullough CS, So SK, Marsh JW, Rush T, Michalski S, Phelan D, Mohanakumar T. Hanto DW, et al. Transplant Proc. 1991 Feb;23(1 Pt 2):1050-1. Transplant Proc. 1991. PMID: 1899150 Clinical Trial. No abstract available.
• The effect of induction ALG (MALG) on the outcome of steroid-resistant rejection treated with OKT3 in renal transplant patients.

  Chiu A, Landsberg D, Cameron EC, Manson AD, Shackleton C. Chiu A, et al. Transplant Proc. 1991 Feb;23(1 Pt 2):1039-40. Transplant Proc. 1991. PMID: 1899146 No abstract available.
• MALG vs OKT3 following renal transplantation: a randomized prospective trial.

  Frey DJ, Matas AJ, Gillingham KJ, Canafax D, Payne WD, Dunn DL, Sutherland DE, Najarian JS. Frey DJ, et al. Transplant Proc. 1991 Feb;23(1 Pt 2):1048-9. Transplant Proc. 1991. PMID: 1899149 Clinical Trial. No abstract available.
• Acute renal allograft rejection: the role of monoclonal antibodies in treatment: experience with orthoclonal anti-T3 cell antibody.

  McLigeyo SO, Notghi A, Anderton JL, Dick J. McLigeyo SO, et al. East Afr Med J. 1990 Sep;67(9):667-73. East Afr Med J. 1990. PMID: 2123786 Review.
• Strategies of immunosuppression in cardiac transplantation.

  Renlund DG, O'Connell JB, Bristow MR. Renlund DG, et al. Semin Thorac Cardiovasc Surg. 1990 Apr;2(2):181-8. Semin Thorac Cardiovasc Surg. 1990. PMID: 2127901 Review.